logo
  

Cameron International Q2 Profit Rises, Lifts 2014 Earnings Outlook - Quick Facts

Cameron International Corp. (CAM), a provider of flow equipment products, Thursday reported second-quarter net income attributable to stockholders of $221 million or $1.08 per share, up from $140 million or $0.57 per share in the previous year.

The latest quarter's results include unusual items consisting of after-tax credits of $0.02 per share and a gain of $0.06 per share from discontinued operations. The unusual items for the year-ago period were charges and the tax consequences related to the formation of OneSubsea of $0.22 and a gain of $0.02 per share from discontinued operations.

Excluding items, adjusted earnings for the recent quarter totaled $1.00 per share, compared to $0.77 per share in the same period last year. On average, 28 analysts polled by Thomson Reuters expected the company to earn $0.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues for the quarter grew nearly 20 percent to $2.64 billion from $2.21 billion in the prior year. Analysts estimated revenues of $2.56 billion for the quarter.

Looking ahead to the third quarter, Camron forecasts earnings from continuing operations in a range of $1.10 to $1.20 per share excluding unusual items. Street expects the company to report earnings of $1.08 per share for the quarter.

For fiscal 2014, Cameron now expects adjusted earnings from continuing operations in a range of $4.00 to $4.25 per share, up from the prior range of $3.80 to $4.10 per share, excluding unusual items. Analysts expect earnings of $3.93 per share for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT